• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2012 年至 2018 年某医院耐药特征与抗菌药物使用密度的相关性分析。

Correlation Analysis between the Characteristics of Resistance and the Antibiotic Use Density in a Hospital from 2012 to 2018.

机构信息

Department of Ultrasound, The Eighth Medical Center, Chinese PLA General Hospital, Beijing, China.

Western Medical Distict of Chinese PLA General Hospital, Beijing, China.

出版信息

J Healthc Eng. 2021 Nov 11;2021:5031667. doi: 10.1155/2021/5031667. eCollection 2021.

DOI:10.1155/2021/5031667
PMID:34804452
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8601808/
Abstract

OBJECTIVE

To explore the correlation between the resistance characteristics of (HP) and antibiotic use density (AUD) in a hospital from 2012 to 2018.

METHODS

HP strains isolated from Chinese PLA General Hospital from 2012 to 2018 were collected to analyze the drug resistance of clarithromycin, levofloxacin, amoxicillin, and metronidazole, and their correlation with the AUD of the outpatient department and inpatient department was analyzed, respectively.

RESULTS

From 2012 to 2018, metronidazole-resistant strains accounted for the largest proportion, followed by clarithromycin and levofloxacin, and amoxicillin-resistant strains accounted for the least. In 2012-2018, the resistance rate of clarithromycin, levofloxacin, amoxicillin, and metronidazole has basically increased year by year; from 2012 to 2018, the highest outpatient AUD in a hospital was amoxicillin, followed by clarithromycin and levofloxacin, metronidazole was the lowest, and the inpatient AUD from high to low was levofloxacin, metronidazole, amoxicillin, and clarithromycin. The drug resistance rate of HP in the hospital from 2012 to 2018 was positively correlated with the AUD of clarithromycin ( = 0.884, =0.017) and levofloxacin ( = 0.934, =0.002) in the outpatient department.

CONCLUSIONS

has the strongest resistance to metronidazole and the worst resistance to amoxicillin in the hospital from 2012 to 2018, being related to the intensity of clarithromycin and levofloxacin in the outpatient department. It may provide certain reference significance for the clinical treatment of .

摘要

目的

探讨 2012 年至 2018 年期间某医院幽门螺杆菌(HP)耐药性与抗生素使用密度(AUD)的相关性。

方法

收集 2012 年至 2018 年中国人民解放军总医院分离的 HP 菌株,分析克拉霉素、左氧氟沙星、阿莫西林和甲硝唑的耐药性,并分别分析其与门诊和住院部 AUD 的相关性。

结果

2012 年至 2018 年,甲硝唑耐药菌株所占比例最大,其次为克拉霉素和左氧氟沙星,阿莫西林耐药菌株所占比例最小。2012-2018 年,克拉霉素、左氧氟沙星、阿莫西林和甲硝唑的耐药率基本呈逐年上升趋势;2012 年至 2018 年,医院门诊 AUD 最高的是阿莫西林,其次是克拉霉素和左氧氟沙星,甲硝唑最低,住院 AUD 由高到低分别是左氧氟沙星、甲硝唑、阿莫西林和克拉霉素。2012 年至 2018 年医院 HP 耐药率与门诊克拉霉素( = 0.884, =0.017)和左氧氟沙星( = 0.934, =0.002)AUD 呈正相关。

结论

2012 年至 2018 年期间,医院中 HP 对甲硝唑的耐药性最强,对阿莫西林的耐药性最差,与门诊克拉霉素和左氧氟沙星的强度有关。这可能为临床治疗 HP 提供一定的参考意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca5d/8601808/9b2fa40db7d6/JHE2021-5031667.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca5d/8601808/9b2fa40db7d6/JHE2021-5031667.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca5d/8601808/9b2fa40db7d6/JHE2021-5031667.001.jpg

相似文献

1
Correlation Analysis between the Characteristics of Resistance and the Antibiotic Use Density in a Hospital from 2012 to 2018.2012 年至 2018 年某医院耐药特征与抗菌药物使用密度的相关性分析。
J Healthc Eng. 2021 Nov 11;2021:5031667. doi: 10.1155/2021/5031667. eCollection 2021.
2
Primary and secondary clarithromycin, metronidazole, amoxicillin and levofloxacin resistance to Helicobacter pylori in southern Poland.波兰南部幽门螺杆菌对克拉霉素、甲硝唑、阿莫西林和左氧氟沙星的原发和继发耐药性。
Pharmacol Rep. 2011;63(3):799-807. doi: 10.1016/s1734-1140(11)70592-8.
3
Antibiotic resistance of Helicobacter pylori in Chinese children: A multicenter study from 2016 to 2023.中国儿童幽门螺杆菌的抗生素耐药性:一项 2016 年至 2023 年的多中心研究。
Helicobacter. 2024 Jan-Feb;29(1):e13038. doi: 10.1111/hel.13038. Epub 2023 Nov 20.
4
[Preliminary study on in-vitro induction of antibiotic resistance in Helicobacter pylori strains isolated from children].[儿童幽门螺杆菌分离株体外诱导抗生素耐药性的初步研究]
Zhonghua Er Ke Za Zhi. 2007 Sep;45(9):708-11.
5
Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan.台湾地区基于克拉霉素治疗前后幽门螺杆菌对甲硝唑、克拉霉素和左氧氟沙星的耐药性
J Gastroenterol Hepatol. 2009 Jul;24(7):1230-5. doi: 10.1111/j.1440-1746.2009.05829.x. Epub 2009 May 19.
6
ANTIBIOTIC RESISTANCE SURVEILLANCE OF HELICOBACTER PYLORI AT THE BIOBÍO REGION (CHILE) IN A DECADE.十年间智利比奥比奥地区幽门螺杆菌的抗生素耐药性监测
Arq Gastroenterol. 2019 Oct-Dec;56(4):361-366. doi: 10.1590/S0004-2803.201900000-72.
7
Characteristics of phenotypic antibiotic resistance of Helicobacter pylori and its correlation with genotypic antibiotic resistance: A retrospective study in Ningxia.宁夏地区幽门螺杆菌表型耐药特征及其与基因型耐药的相关性:一项回顾性研究。
Helicobacter. 2023 Jun;28(3):e12960. doi: 10.1111/hel.12960. Epub 2023 Apr 11.
8
The effect of previous eradication failure on antibiotic resistance of Helicobacter pylori: A retrospective study over 8 years in Beijing.既往根除失败对幽门螺杆菌耐药性的影响:北京 8 年回顾性研究。
Helicobacter. 2021 Aug;26(4):e12804. doi: 10.1111/hel.12804. Epub 2021 Apr 16.
9
High incidence of antibiotic resistance amongst isolates of collected in Nottingham, UK, between 2001 and 2018.2001 年至 2018 年间,在英国诺丁汉收集的分离物中,抗生素耐药率很高。
J Med Microbiol. 2023 Nov;72(11). doi: 10.1099/jmm.0.001776.
10
Dynamics of antimicrobial resistance of Helicobacter pylori isolates in the Smolensk region of Russian Federation.俄罗斯联邦斯摩棱斯克地区幽门螺杆菌分离株的抗菌药物耐药性动态。
Helicobacter. 2018 Dec;23(6):e12545. doi: 10.1111/hel.12545. Epub 2018 Oct 16.

引用本文的文献

1
Lean Six Sigma as a Management Tool Helps Standardize Antimicrobial Use in Hospital Settings.精益六西格玛作为一种管理工具有助于规范医院环境中的抗菌药物使用。
Drug Des Devel Ther. 2025 Apr 30;19:3539-3554. doi: 10.2147/DDDT.S510926. eCollection 2025.
2
Retracted: Correlation Analysis between the Characteristics of Resistance and the Antibiotic Use Density in a Hospital from 2012 to 2018.撤回:2012年至2018年某医院耐药特征与抗生素使用密度的相关性分析。
J Healthc Eng. 2023 Dec 6;2023:9867583. doi: 10.1155/2023/9867583. eCollection 2023.

本文引用的文献

1
[Effectiveness of eradication regimen based on the bacterial susceptibility and CYP2C19 genotype in children with refractory infection].基于细菌药敏及CYP2C19基因分型的根除方案对难治性感染患儿的疗效
Zhonghua Er Ke Za Zhi. 2020 Jan 2;58(1):41-45. doi: 10.3760/cma.j.issn.0578-1310.2020.01.010.
2
The antibiotic resistance of Helicobacter pylori to five antibiotics and influencing factors in an area of China with a high risk of gastric cancer.中国胃癌高发地区幽门螺杆菌对五种抗生素的耐药性及其影响因素。
BMC Microbiol. 2019 Jul 4;19(1):152. doi: 10.1186/s12866-019-1517-4.
3
Study of rdxA and frxA genes mutations in metronidazole-resistant and -susceptible Helicobacter pylori clinical isolates from the central region of Portugal.
葡萄牙中部地区甲硝唑耐药和敏感的幽门螺杆菌临床分离株中 rdxA 和 frxA 基因突变的研究。
J Glob Antimicrob Resist. 2019 Jun;17:300-304. doi: 10.1016/j.jgar.2019.01.008. Epub 2019 Jan 15.
4
Helicobacter pylori evasion strategies of the host innate and adaptive immune responses to survive and develop gastrointestinal diseases.幽门螺杆菌逃避宿主固有和适应性免疫应答的策略,以在胃肠道疾病中存活和发展。
Microbiol Res. 2019 Jan;218:49-57. doi: 10.1016/j.micres.2018.09.011. Epub 2018 Oct 6.
5
Anti-Helicobacterpylori effectiveness and targeted delivery performance of amoxicillin-UCCs-2/TPP nanoparticles based on ureido-modified chitosan derivative.基于脲基修饰壳聚糖衍生物的阿莫西林-UCCs-2/TPP 纳米粒的抗幽门螺杆菌效果和靶向递药性能。
Int J Biol Macromol. 2018 Aug;115:367-374. doi: 10.1016/j.ijbiomac.2018.04.070. Epub 2018 Apr 14.
6
Impact of primary antibiotic resistance on the effectiveness of sequential therapy for Helicobacter pylori infection: lessons from a 5-year study on a large number of strains.原发性抗生素耐药性对幽门螺杆菌感染序贯疗法疗效的影响:一项针对大量菌株的 5 年研究的经验教训。
Aliment Pharmacol Ther. 2018 May;47(9):1261-1269. doi: 10.1111/apt.14597. Epub 2018 Mar 14.
7
Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy.沃诺拉赞,一种新型钾离子竞争型酸阻滞剂,应作为幽门螺杆菌根除治疗的首选药物:一项使用沃诺拉赞的真实世界大样本研究与我们使用第二代质子泵抑制剂进行的幽门螺杆菌根除治疗的随机对照试验比较。
Digestion. 2018;97(3):212-218. doi: 10.1159/000485097. Epub 2018 Jan 31.
8
Gastric bacterial Flora in patients Harbouring Helicobacter pylori with or without chronic dyspepsia: analysis with matrix-assisted laser desorption ionization time-of-flight mass spectroscopy.患有或未患有慢性消化不良的幽门螺杆菌携带者的胃内细菌菌群:采用基质辅助激光解吸电离飞行时间质谱法进行分析
BMC Gastroenterol. 2018 Jan 26;18(1):20. doi: 10.1186/s12876-018-0744-8.
9
Efficacy of Reduced Dosage of Amoxicillin in an Eradication Therapy for Helicobacter pylori Infection in Patients on Hemodialysis: A Randomized Controlled Trial.减少剂量阿莫西林在血液透析患者幽门螺杆菌感染根除治疗中的疗效:一项随机对照试验。
Digestion. 2018;97(2):163-169. doi: 10.1159/000484981. Epub 2018 Jan 8.
10
MicroRNA-222-3p associated with Helicobacter pylori targets HIPK2 to promote cell proliferation, invasion, and inhibits apoptosis in gastric cancer.微小 RNA-222-3p 与幽门螺杆菌相互作用,靶向 HIPK2 促进胃癌细胞增殖、侵袭,抑制凋亡。
J Cell Biochem. 2018 Jul;119(7):5153-5162. doi: 10.1002/jcb.26542. Epub 2018 Mar 25.